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Abstract
Background: Female patients with cystic fibrosis (CF) have consistently poorer survival rates than
males across all ages. To determine if gender differences exist in health-related quality of life
(HRQOL) of adolescent patients with CF, we performed a cross-section analysis of CF patients
recruited from 2 medical centers in 2 cities during 1997–2001.
Methods: We used the 87-item child self-report form of the Child Health Questionnaire to
measure 12 health domains. Data was also collected on age and forced expiratory volume in 1
second (FEV1). We analyzed data from 98 subjects and performed univariate analyses and linear
regression or ordinal logistic regression for multivariable analyses.
Results: The mean (SD) age was 14.6 (2.5) years; 50 (51.0%) were female; and mean FEV1 was
71.6% (25.6%) of predicted. There were no statistically significant gender differences in age or FEV1.
In univariate analyses, females reported significantly poorer HRQOL in 5 of the 12 domains. In
multivariable analyses controlling for FEV1 and age, we found that female gender was associated
with significantly lower global health (p < 0.05), mental health (p < 0.01), and general health
perceptions (p < 0.05) scores.
Conclusion: Further research will need to focus on the causes of these differences in HRQOL
and on potential interventions to improve HRQOL of adolescent patients with CF.
Background
Cystic fibrosis (CF) is a genetic disorder that affects multi-
ple organ systems. Treatments have improved overall sur-
vival so that those born today have a median life
expectancy of approximately 40 years [1]. Much of the
morbidity and mortality associated with cystic fibrosis is
due to pulmonary disease, and investigations have shown
that early, aggressive, and center-based care improves
prognosis [2]. Objective clinical parameters, such as aero-
bic fitness, pulmonary function, nutritional status, and
aggressive treatment with antibiotics, are associated with
improved health outcomes [2]. In the past, clinical mor-
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bidity and mortality rates in children and adolescents
were monitored as primary outcomes [3], but more
recently, to provide the scientific basis for practice guide-
lines and to measure treatment effectiveness from
patients' perspectives, there has been increasing focus on
the examination of health-related quality of life (HRQOL)
[4,5], Thus, the Cystic Fibrosis Foundation and the
National Heart, Lung, and Blood Institute recommend
incorporating quality of life as an outcome measure for
patients with CF [6]. In CF populations, the measurement
of HRQOL is one approach that has been used to correlate
clinical outcomes and the impact of both disease progres-
sion and treatments from patients' perspectives [7-9].
Many factors have been shown to influence survival in
patients with CF. Biologic and physiologic factors such as
pancreatic insufficiency and pseudomonas infections, and
socioeconomic factors such as inadequate or no health
insurance are associated with decreased survival rates
[2,10,11]. Britto found that, compared with the general
population, patients with CF report lower physical health
scores, independent of lung function, nutritional status or
demographic factors [12]. Moreover, female patients with
CF have been shown across age strata to have a shorter life
expectancy, more serious respiratory infections, and Pseu-
domonas aeruginosa infections at a younger age than male
patients, although the etiology of gender differences is
unclear [13-15]. Also, higher health values, including
higher time tradeoff (TTO) scores, have been linked to
male gender in patients with CF [16].
In other populations, studies have shown that gender
plays a part in the way patients – including adolescents –
perceive their own HRQOL and health status [17-21,30].
Adult female patients with chronic illnesses have reported
poorer HRQOL than males in prior studies [22-25]. Evi-
dence suggests that, in general, men and women may
respond differently to poor health and women may, in
turn, report poorer general health than men [26-30]. This
difference has also been seen among adolescents. In one
European study, adolescent females reported lower
HRQOL with regard to physical health, mood, and self
perception than adolescent males. [31] This difference
was noted to have developed around age 12 and persisted
through late adolescence.
Few studies have examined how the gender of patients
with CF may impact their HRQOL when accounting for
the severity of illness [32-35]. With this investigation, we
wanted to determine if gender differences exist in self-
reported HRQOL in adolescents with CF. Our specific
objectives were: 1) to determine if there are gender differ-
ences in HRQOL in adolescent patients with CF; and 2) to
determine which HRQOL domains are associated with
differences when stratified by gender, after controlling for
markers of disease severity. We hypothesized that gender
differences exist, with female adolescents reporting poorer
HRQOL than males.
Methods
Study design
We performed analyses of data from two previously pub-
lished cross-sectional questionnaire studies of adolescent
outpatients with CF [12,16]. The combined datasets were
used to evaluate for gender differences in adolescents with
CF.
Recruitment and data collection
In each of the prior studies, subjects previously diagnosed
with CF were recruited from Cincinnati Children's Hospi-
tal Medical Center in Cincinnati, Ohio and The Children's
Medical Center in Dayton, Ohio between 1997–2001.
Patients and their families were invited to participate in
each of the prior studies by either a physician or a research
coordinator at the time of their regularly scheduled quar-
terly clinic appointment, by telephone, or by mail.
Patients in each study were recruited and completed the
questionnaire in the same manner. Patients between 10
and 18 years of age were recruited, and we excluded
patients with CF who had undergone lung transplanta-
tion. Informed consent was obtained from the patient. If
the patient was younger than 18 years, informed consent
was obtained from the parent or guardian and assent was
obtained from the patient. The study was approved by the
institutional review boards at both participating sites.
Health-related quality of life measures
The Child Health Questionnaire (CHQ) was used to
measure the adolescent's HRQOL in each of the prior
studies [36]. The CHQ is a generic health status instru-
ment that has been validated, used in a number of popu-
lations with chronic illness, including adolescents with
CF, and found to be reliable [12,16,37-39]. The Child
Form-87 (CF-87) of the CHQ was designed to measure 12
health domains: global health – subjective overall health;
physical functioning – physical limitations due to health-
related problems; bodily pain – intensity and frequency of
general pain and discomfort; behavior – aggression, delin-
quency, hyperactivity/impulsivity and social withdrawal;
mental health – anxiety, depression and positive affect;
self esteem – satisfaction with school and athletic ability,
looks/appearance, ability to get along with others and
family, and life overall; general health perceptions – sub-
jective assessment of past, future and current health and
resistance/susceptibility to sickness; family cohesion –
how well the patient's family gets along with one another;
family activities – frequency of family activities; role limi-
tations due to physical, emotional, and behavioral prob-
lems; and change in health in the past year. On each
subscale, a score of 0 represents worst functioning andHealth and Quality of Life Outcomes 2006, 4:5 http://www.hqlo.com/content/4/1/5
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100 represents best functioning, except for a change in
health, where "1" represents health much worse than 1
year ago, "2" represents health somewhat worse than 1
year ago, "3" represents health about the same as 1 year
ago, "4" represents health somewhat better than 1 year
ago, and "5" represents health much better than 1 year
ago. The highest possible score indicates the absence of a
negative state, whereas lower scores indicate greater limi-
tations in the HRQOL domain.
Clinical measures
Data were collected on age, gender, and forced expiratory
volume in 1 second (FEV1). Pulmonary function and exac-
erbations have been associated with differences in
HRQOL in adults and older adolescents [12]. Pulmonary
function was determined by using spirometry and total
body plethysmography according to American Thoracic
Society Standards (American Thoracic Society 1991).
Demographic data and clinical data were obtained from
the CHQ or clinic chart review.
Statistical analysis
All analysis were performed with SAS software, version 8.0
(SAS Institute, Inc, Cary, NC). Comparisons between con-
tinuous variables were conducted using two-tailed t tests
and comparisons between categorical variables were con-
ducted using χ2 tests. We used multivariable linear regres-
sion analysis to determine if the independent variable
(gender) was associated with the outcome variable (each
Table 1: Characteristics of Participants
Gender Patients, # (%) Age, yr (SD) FEV1, %predicted(SD)
Female 50 (51%) 14.5 (2.8) 67 (26)
Male 48 (49%) 14.6 (2.2) 76 (25)
P-Value 0.80 0.07
Table 2: Health-related quality of life by gender
Domain Mean (SD) Median Interquartile range 
(IQR)
Females
Global Health* 65 (23) 60 60 85
Physical Functioning* 86 (17) 92.6 81.5 100
Bodily Pain 67 (24) 70 50 80
Behavior* 79 (15) 83.6 72 88
Mental Health* 70 (19) 76.6 61.7 85.2
Self-esteem* 77 (16) 78.6 66.1 89.3
General Health Perception* 49 (20) 49.8 34.6 63.3
Family Cohesion* 74 (23) 85 60 85
Family Activities* 71 (21) 75 50 87.5
Role/social Emotional 86 (18) 100 77.8 100
Role/social Physical 92 (18) 100 66.7 100
Role/social Behavioral 87 (20) 100 100 100
Change in Health 3.6 (1.2) 4.0 3.0 5.0
Males
Global Health* 79 (24) 85 60 100
Physical Functioning* 91 (14) 100 87.0 100
Bodily Pain 71 (22) 80 60 80
Behavior* 84 (11) 87.1 78.5 92.2
Mental Health* 80 (13) 82.8 70.3 90.3
Self-esteem* 82 (18) 87.5 67.9 96.4
General Health Perception* 62 (21) 61.3 48.3 77.9
Family Cohesion* 81 (16) 85 60 92.5
Family Activities* 80 (21) 83.3 70.8 95.8
Role/social Emotional 90 (20) 100 88.9 100
Role/social Physical 90 (21) 100 88.9 100
Role/social Behavioral 91 (19) 100 94.4 100
Change in Health 3.7 (1.0) 4 3 5
*P value < 0.05 in univariate analysis comparing males and femalesHealth and Quality of Life Outcomes 2006, 4:5 http://www.hqlo.com/content/4/1/5
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CHQ subscale), controlling for FEV1 and age. Because of
the categorical nature of the GH outcome variable, we per-
formed multivariable analysis by using ordinal logistic
regression. Each variable was entered into multivariable
linear regression if in univariate analysis it had a signifi-
cance level equal to or greater than 0.20. Because some the
variables were not normally distributed, to assess the
robustness of our results, we repeated all of the compari-
sons using non-parametric methods and the results were
qualitatively the same. We found the parametric univari-
ate comparisons to be consistent with the parametric mul-
tivariable methods. We also performed the regressions
with the outcome log transformed and the results were
qualitatively identical. The non-transformed results are
presented for ease of interpretation.
Although there is currently no "gold standard" or consen-
sus by which the clinical importance of differences
HRQOL scores can be determined, methods have been
proposed to estimate clinically important differences
(CID) in HRQOL [40-43]. In one approach, the minimal
clinically important difference [MCID] is defined by an
effect size of >0.20, where effect size = [meanM-meanF]/
[SDM] [40]. In this schema, effect sizes of 0.20–0.49 indi-
cate 'small' effect sizes, 0.50–0.79 indicate 'moderate'
effect sizes, and >0.80 indicate 'large' effect sizes. We used
effect sizes of differences in HRQOL between males (M)
and females (F) to assess for clinically important differ-
ences.
Results
Ninety-eight adolescents aged 10–18 years completed the
CF-87 (Table 1). The mean (SD) age was 14.6 (2.5) years;
50 (51.0%) were female; and the mean (SD) FEV1 was
71.6% (25.6%) of predicted. There were no significant
differences between males and females for age or FEV1.
Table 2 summarizes the mean, SD, range, and percent at
the floor and ceiling for each scale.
Health status
Female adolescents with CF reported poorer HRQOL than
males in all 12 of the domains except for the role behav-
ioral domain (Table 2). In univariate analysis, females
reported significantly poorer health in the global health,
physical functioning, mental health, general health per-
ceptions, and family activity domains (p < 0.05; Figure 1;
Table 2). There were no significant differences noted
between males and females for the change in health
domain.
Three health domains of the CHQ showing statistically
significant gender differences in the multivariate models
demonstrate an effect size that is moderately clinically
important between males and females: the global health,
mental health and general health perception scales (Fig-
ure 2). The difference in role physical domain was nega-
tive because males reported poorer HRQOL in the role
physical domain than females.
In multivariable analyses controlling for age and FEV1,
females reported poorer global health, mental health, and
general health perceptions (p < 0.05; Table 3). Gender was
no longer significantly associated with physical function-
ing and family activities when controlling for age and
FEV1.
Discussion
Female patients with CF have been shown to have much
shorter life expectancies than males with CF, with a
median decrease of 4 years until the age of 20 [14,44]. We
sought to determine if gender differences exist for HRQOL
for adolescent patients with CF.
In our cohort of adolescents with CF, significant gender
differences in HRQOL existed between males and females.
On average, female adolescents with CF scored lower on
all health domains with the exception of the role behavior
domain. Even when controlling for age and lung disease
severity, female adolescents had significantly lower scores
in mental health, global health, and perceptions of gen-
eral health. Physical functioning was not related to gender
when controlling for age and lung disease severity. This
may indicate that age and disease severity is more impor-
tant than gender in predicting physical aspects of HRQOL.
In addition, the level of family activities, which may also
Health-Related Quality of Life by Domain and Gender Figure 1
Health-Related Quality of Life by Domain and Gen-
der. Health scores ranging from 0–100 are shown on the Y-
axis and domains on the X-axis. The asterix (*) indicates p-
value < 0.05 for the difference between males and females. 
Domains: Global Health (GH); Physical Functioning (PF); 
Bodily Pain (BP); Behavior (BE); Mental Health (MH); Self-
esteem (SE); General Health Perception (GP); Family Cohe-
sion (FC); Family Activities (FA); Role/social Physical; Role/
social Emotional (RE); Role/social Behavioral (RB).
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be influenced by age of the patient and severity of lung
disease, were no longer significant when controlling for
those factors.
Previous research has found that female adolescents with
CF have a more accurate perception of objective clinical
health status than male adolescents [26], but rely more on
denial to cope [45]. Such negative ways of coping can
result in poor correlation between pulmonary function
and general health perceptions. When compared to ado-
lescent males, adolescent women, have also been found to
use more of both positive and negative coping strategies
to withstand pain [34,46,47]. Avoidance strategies may be
viewed as 'negative' or maladaptive by health profession-
als if it means that patients avoid doing their treatments,
but from the perspective of patients may be psychologi-
cally adaptive as a means to escape the world of CF for a
while. Additionally, some studies have found that adoles-
cent females report more physical health symptoms, psy-
chological symptoms and use more emotion-oriented
and problem oriented coping strategies than adolescent
males. [48] Because coping styles may be associated with
medication adherence, gender differences and coping
skills need to be considered when correlating clinical
markers with changes in HRQOL.
From a developmental psychology perspective, changes in
HRQOL may be explained by hormonal development as
well as a physical and social transition from childhood to
adulthood. As adolescents transition, peer and social
groups emerge, cognitive abilities develop, and they
become more independent from their families. This stage
of development may affect perceived physical health.
Some have described that perceived health is determined
by personal factors such as gender, school achievement,
drug use, health behaviors, and the adolescents' environ-
ment, such as peer/parent relationships and the family's
income [49]. Others have linked risk-taking behaviors to
lower family income [50]. However, some data suggest
that gender differences play a more significant role than
class differences with regard to differences in health [51].
Similar to studies done in non-CF populations [31], we
found gender differences among adolescents with CF in
the areas of mental health and general health perceptions.
Differences in physical functioning did not persist in this
study possibly because body image also contributes to
one's perception of physical health and physical function-
ing is linked to pulmonary function. Studies have shown
little difference in body image between patients with CF
and healthy age-matched controls [52]. Females more
often overestimate their weight, while males underesti-
mate their weight. A significantly greater proportion of
Effect Sizes for Gender Differences in HRQOL Figure 2
Effect Sizes for Gender Differences in HRQOL. The domains of HRQOL are shown on the X-axis and the effect size on 
the Y-axis where effect size = [meanM-meanF]/SDM. Effect sizes between 0.2 and 0.5 are felt to be minimally clinically important 
and those between 0.5 and 0.8 are felt to be moderately clinically important. Positive effect sizes indicate better HRQOL for 
males than females. Role physical (RP) domain is negative because males reported worse HRQOL than females. Domains: 
Global Health (GH); Physical Functioning (PF); Bodily Pain (BP); Behavior (BE); Mental Health (MH); Self-esteem (SE); General 
Health Perception (GP); Family Cohesion (FC); Family Activities (FA); Role/social Physical; Role/social Emotional (RE); Role/
social Behavioral (RB).
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males than females perceived their weight status as under-
weight and therefore, were more likely to take enteral sup-
plements [53]. Willis and colleagues [54], found that
young men and women with CF identify first as young
men and women, rather than adults with CF. This com-
bined with social desires to stay slender, has been sug-
gested to contribute to non-adherence.
Powers [55] found that adolescents reported strong rela-
tionships between pulmonary function and self-reports of
pain, general health, and school-activity limitations, but
pulmonary function was not related to physical function-
ing, emotional or behavioral health. Perhaps because gen-
der differences factor into global health, physical
function, and general health perception among adoles-
cents, such a relationship with pulmonary function is not
established. In this study, female adolescents with CF
reported poorer mental health, global health, and general
health perceptions. Such gender differences might limit
associations between pulmonary function and certain
health domains when the effect of gender is not taken into
account.
There are some limitations of this study. Although we
recruited patients from 2 CF centers, the sample size was
relatively small. A few of the health domains exhibited
ceiling effects. The CHQ is a generic questionnaire used to
measure HRQOL in diverse pediatric populations and
may not have been able to detect small differences in
HRQOL in patients with CF. Accordingly, the generaliza-
bility of our findings is uncertain. Because we examined
HRQOL in two prior completed studies, we were unable
to examine HRQOL differences in those who refused and
those who agreed to participate. Patients with more severe
disease (with greater likelihood of being females) may
have participated in the study at disproportionately low
rates when compared with healthier counterparts. For
example, in our population, the overall FEV1 was reflective
of mild disease. Clinical variables, such as pseudomonal
infection, nutrition status, and history of co morbidities
such as diabetes, and social variables such as socioeco-
nomic or insurance status, were not available for many
observations and thus were not controlled for, which may
partially explain the HRQOL differences we found
between genders.
Multiple studies have shown that females, including ado-
lescents, report poorer HRQOL than males [8,18,20,56],
often despite having similar objective clinical  measures
like pulmonary function. It is possible that such differ-
ences were based on perception of health, rather than
actual health status. Females had poorer HRQOL in pri-
marily the psychological domains of health, when con-
trolling for disease severity and age. The psychological
domains of health may potentially affect therapy and
should be considered when treating female adolescents
with cystic fibrosis. Other social constructs that affect ado-
lescent skill building, including self-construct, self-effi-
cacy, identity formation and social support may be
responsible for overall health perceptions in adolescent
males and females.
Conclusion
Gender differences in HRQOL appear to exist between
adolescent males and females with CF. Further research
will need to focus on the causes of such gender differences
in HRQOL and on potential interventions to improve
HRQOL for all adolescents living with CF.
Competing interests
The author(s) declare they have no competing interests.
Authors' contributions
RA, MY, JT, RW, JM and MB worked on the conception
and design. Acquisition of data was performed by MY and
MB. Analysis and interpretation of data was performed by
RA, MY, JM and MB. The manuscript was drafted by RA,
MY and MB. RA, MY, JT, JM, RW and MB were involved in
critical revision of the manuscript for important intellec-
tual content. Statistical analysis performed by RA, MY,
and JM. MY, JT, JM, RW and MB provided administrative,
technical, or material support. Study supervision was per-
formed by MY, JT, RW and MB.
Acknowledgements
Dr. Yi is supported by a National Institute of Child and Human Develop-
ment Career Development Award. (K23HD046690). Dr. Tsevat is sup-
ported by a National Center for Complementary and Alternative Medicine 
award (K24 AT001676). Dr. Mrus was a recipient of a Career Development 
Award (RCD 01011-2) from the Department of Veterans Affairs, Health 
Services Research and Development Service. Dr. Britto was funded by 
Cystic Fibrosis Foundation Grant (BRITTO98A0).
References
1. Elborn JS, Shale DJ, Britton JR: Cystic fibrosis: current survival
and population estimates to the year 2000.  Thorax 1991,
46:881-885.
2. Orenstein DM, Winnie GB, Altman H: Cystic fibrosis: A 2002
update.  J Pediatr 2002, 140:156-164.
3. American Medical Association: Profiles of Adolescent Health Series Chi-
cago, IL: American Medical Association; 1990. 
4. Newacheck PW, Taylor WR: Childhood chronic illness: preva-
lence, severity and impact.  Am J Public Health 1992, 82:364-371.
Table 3: Domains with significant gender differences in 
multivariable models
β-Coefficient P value R2
Global Health (GH) 1.1 <0.05 0.44*
Mental Health (MH) 10.4 <0.01 0.09
General Health Perception (GP) 9.7 <0.05 0.21
* Somers' D, used for logistic procedure; multivariable model 
controlling for age and FEV1Health and Quality of Life Outcomes 2006, 4:5 http://www.hqlo.com/content/4/1/5
Page 7 of 8
(page number not for citation purposes)
5. Koppleman J: Meeting the needs of chronically disabled chil-
dren in changing health care system.  National Health Policy
Forum Issue Brief 1994, 651:1-9.
6. Eigen H, Clark NM, Wolle JM: NHLBI Workshop summary: clin-
ical behavioral aspects of cystic fibrosis; directions for future
research.  Am Rev Respir Dis 1987, 136:1509-1513.
7. Orenstein DM, Nixon PA, Ross EA, Kaplan RM: The quality of well-
being in cystic fibrosis.  Chest 1989, 95:344-347.
8. Gee L, Abbott J, Conway SP, Etherington C, Webb AK: Develop-
ment of disease specific health related quality of life measure
for adults and adolescents with cystic fibrosis.  Thorax 2000,
55:946-954.
9. Busschbach JJ, Horikx PE, van den Bosch JM, de la Riviere A, de
Charro FT: Measuring the quality of life before and after bilat-
eral lung transplantation in patients with cystic fibrosis.  Chest
1994, 105:911-917.
10. Curtis JR, Burke W, Kassner AW, Aitken ML: Absence of health
insurance is associated with decreased life expectancy in
patients with cystic fibrosis.  Am J Respir Crit Care Med 1997,
155:1921-1924.
11. Schechter MS, Margolis PA: Relationship between socioeco-
nomic status and disease severity in cystic fibrosis.  J Pediatr
1998, 132:260-264.
12. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J,
Wilmott R: Impact of recent pulmonary exacerbations on
quality of life in patients with cystic fibrosis.  Chest 2001,
121:64-72.
13. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B: Gender
gap in cystic fibrosis mortality.  Am J Epidemiol 1997,
145:794-803.
14. FitzSimmons SC: The changing epidemiology of cystic fibrosis.
J Pediatr 1993, 122:1-9.
15. Demko CA: Gender differences in cystic fibrosis: Pseudomonas
aeurginosa infection.  J Clin Epidemiol 1995, 48:1041-1049.
16. Yi MS, Britto MT, Wilmott RW, Kotagal UR, Eckman MH, Nielson
DW, Kociela VL, Tsevat J: Health values of adolescents with
cystic fibrosis.  J Pediatr 2003, 142:133-40.
17. Sawyer SM, Rosier MJ, Phelam PD, Bowes G: The self-image of
adolescents with cystic fibrosis.  J Adolesc Health 1995,
16:204-208.
18. Wijnhoven HA, Kriegsman DM, Snoek FJ, Hesselink AE, de Haan M:
Gender differences in health-related quality of life among
asthma patients.  J Asthma 2003, 40:189-199.
19. Vingilis ER, Wade TJ, Seeley JS: Predictors of adolescent self-
rated health: analysis of the National Population Health Sur-
vey.  Can J Public Health 2002, 93:193-197.
20. Goodman E, Amick BC, Rezendes MO, Tarlov AR, Rogers WH,
Kagan J: Influences on gender and social class on adolescents'
perceptions of health.  Arch Pediatr Adolesc Med 1997,
151:899-904.
21. Heinonen H, Volin L, Uutela A, Zevon M, Barrick C, Ruutu T: Gen-
der-associated differences in quality of life after allogenic
BMT.  Bone Marrow Transplant 2001, 28:503-509.
22. De Vries J, Van Heck GL, Drent M: Gender differences in sar-
coidosis: symptoms, quality of life, and medical consump-
tion.  Women Health 1999, 30:99-114.
23. Riedinger MS, Dracup KA, Brecht ML, Padilla G, Sarna L, Ganz PA:
Quality of life in patients with heart failure: Do gender differ-
ences exist?  Heart Lung 2001, 30:105-116.
24. Westbrook JI, Talley NJ, Westbrook MT: Gender differences in
the symptoms and physical and mental well-being of dyspep-
tics: a population based study.  Qual Life Res 2002, 11:283-291.
25. Mrus JM, Williams P, Tsevat J, Cohn SE, Wu AW: Gender differ-
ences in health-related quality of life in patients with HIV/
AIDS.  Qual Life Res 2005, 14:479-491.
26. Mechanic D: Sex illness behaviour and the use of health serv-
ices.  Social Sci Med 1978, 128:207-214.
27. Merrill SS, Seeman TE, Kasl SV, Berkman LF: Gender differences in
the comparison of self reported disability and performance
measures.  J Gerontol A Biol Sci Med Sci 1997, 52:M19-M26.
28. Piccinelli M, Simon G: Gender and cross-cultural differences in
somatic symptoms in association with emotional distress: an
international study in primary care.  Psychol Med 1997,
27:433-44.
29. Unruh AM: Gender variations in clinical pain experience.  Pain
1997, 65:123-67.
30. Macintyre S, Hunt K, Sweeting H: GenderDifferences in health
are things really as simple as they seem?  Soc Sci & Med 1996,
42:617-24.
31. Bisegger C, Cloetta B, von Rueden U, Abel T, Ravens-Sieberer U:
Health-related quality of life: gender differences in childhood
and adolescence.  Soz Praventivmed 2005, 50:281-91.
32. Ruiz MT, Verbrugge LM: A two way view of gender bias in med-
icine.  J Epidemiol Community Health 1997, 51:106-9.
33. Gee L, Abbott J: Quality of Life in cystic fibrosis: the impact of
gender, general health perceptions and disease severity.  J
Cyst Fibros 2003, 2:206-213.
34. Congleton J, Hodson ME, Duncan-Skingle F: Quality of Life in
adults with cystic fibrosis.  Thorax 1996, 51:936-940.
35. Congleton J, Hodson ME, Duncan-Skingle F: Quality of life in adults
with cystic fibrosis.  Thorax 1997, 52:397-400.
36. Landgraf JM, Abetz L, Ware JE, Child Health Questionnaire (CHQ):
A User's Manual.  First edition. Boston, MA: The Health Institute,
New England Medical Center; 1996. 
37. Landgraf JM: Measuring Health Outcomes in Pediatric Populations: Issues
in Psychometrics and Application Philadelphia, PA: Lippincott-Raven;
1996. 
38. Sawyer M, Antoniou G, Toogood I, Rice M: A comparison of par-
ent and adolescent reports describing the health-related
quality of life of adolescents treated for cancer.  Int J Cancer
Suppl 1999, 12:39-45.
39. Homer C, Susskind O, Alpert HR, Owusu M, Schneider L, Rappaport
LA, Rubin DH: An evaluation of an innovative multimedia edu-
cational software program for asthma management: report
of a randomized, controlled trial.  Pediatrics 2000, 106:210-5.
40. Hays RD, Woolley JM: The concept of clinically meaningful dif-
ference in health-related quality-of-life research. How mean-
ingful is it?  Pharmacoeconomics 2000, 18:419-423.
41. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar
D: Determining clinically important differences in health sta-
tus measures: a general approach with illustration to the
Health Utilities Index Mark II.  Pharmacoeconomics 1999,
15:141-155.
42. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes
in health-related quality of life: the remarkable universality
of half a standard deviation.  Med Care 2003, 41:582-92.
43. Farivar SS, Liu H, Hays RD: Half standard deviation estimate of
the minimally important difference in HRQOL scores?  Expert
Review Pharmacoeconomics Outcomes Res 2004, 4:515-523.
44. Davis PB: The gender gap in cystic fibrosis survival.  J Gend Specif
Med 1999, 2:47-51.
45. Simmons RJ, Corey M, Cowen L, Keenan N, Robertson J, Levinson H:
Emotional adjustment of early adolescents with cystic fibro-
sis.  Psychosom Med 1985, 47:111-121.
46. Keefe FJ, Lefebvre JC, Egert J, Affleck G, Sullivan MJ, Caldwell DS: The
relationship of gender to pain, pain behavior, and disability in
osteoarthritis patients: the role of catastrophizing.  Pain 2000,
87:325-334.
47. Keefe FJ, Affleck G, France CR, Emery CF, Waters S, Caldwell DS,
Stainbrook D, Hackshaw KV, Fox LC, Wilson K: Gender differ-
ences in pain, coping, and mood in individuals having oste-
oarthritic knee pain: a within-day analysis.  Pain 2004,
110:571-577.
48. Wilson G, Pritchard ME, Revalee B: Individual differences in ado-
lescent health symptoms: the effects of gender and coping.  J
Adolesc 2005, 28:369-79.
49. Wade TJ, Pevalin DJ, Vingilis E: Revisting student self-rated phys-
ical health.  J Adolesc 2000, 23:785-791.
50. Lowry R, Kann L, Collins JL, Kolbe LJ: The effect of socioeco-
nomic status on chronic disease behaviors among U.S. ado-
lescents.  JAMA 1996, 276:792-797.
51. West P, Macintyre S, Annadale E, Hunt K: Social class and health
in youth: findings from the west of Scotland twenty-07 study.
Soc Sci Med 1990, 30:665-673.
52. Abbott J, Conway S, Etherington C, Fitzjohn J, Gee L, Morton A, Mus-
son H, Webb AK: Perceived body image and eating behavior
in young adults with cystic fibrosis and their healthy peers.  J
Behav Med 2000, 23:501-517.
53. Walters S: Sex differences in weight perception and nutri-
tional behaviour in adults with cystic fibrosis.  J Hum Nutr Diet
2001, 14:83-91.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2006, 4:5 http://www.hqlo.com/content/4/1/5
Page 8 of 8
(page number not for citation purposes)
54. Willis E, Miller R, Wyn J: Gendered embodiment and survival
for young people with cystic fibrosis.  Soc Sci Med 2001,
53:1163-1174.
55. Powers PM: Adolescents with cystic fibrosis: family reports of
adolescent health-related quality of life and forced expira-
tory volume in one second.  Pediatrics 2001, 107:e70.
56. Barr RD, Sek J, Horsman J, Forlong W, Saleh M, Pai M, Walker I:
Health status and health-related quality of life associated
with von Willebrand disease.  Am J Hematol 2003, 73:108-114.